FOR IMMEDIATE RELEASE

Avenor Therapeutics Secures Two Deals to Unlock Heat-Activated Precision Oncology, Uniting a Hyperthermia System and Thermosensitive Drug Platforms Under One Roof

CAMBRIDGE, Mass., November 17, 2026 – Following its incorporation earlier in 2026, Avenor Therapeutics has secured the two assets at the heart of its strategy:

- ALBA, the best-in-class hyperthermia system already treating patients across Europe and Asia; and
- a next-generation of heat-activated tumor targeting drug platform with a Phase II-ready lead candidate.

Two deals, one strategy.

Avenor secured, through a strategic partnership, exclusive North American rights to ALBA, a CE-marked radiative precision hyperthermia platform developed by Medlogix Srl (Rome, Italy), with 74+ systems installed to date across Europe and Asia and a track record in daily clinical use.

Avenor also signed an exclusive worldwide license agreement with Thermosome *GmbH* (Munich, Germany). This agreement covers the thermosensitive liposome (TSL) technology: the Phase II-ready lead candidate THE001, with FDA and EMA Orphan Drug Designation for soft tissue sarcoma, and the entire TSL platform portfolio, with a defined path to full ownership.

Financial terms of the deals were not disclosed.

Together, these transactions position Avenor with a uniquely integrated platform, combining planned, measured heat delivery to the tumor with a thermosensitive drug technology engineered to release its payload precisely at the site of thermal activation.

Global reach. More than a drug. More than a device.

Avenor brings to North America, for regulatory approval and commercialization, a hyperthermia device already in daily clinical use across Europe and Asia. On the drug side, Avenor holds worldwide rights to clinical-stage heat-activated therapeutics, led by THE001, and to the thermosensitive liposome platform behind them, designed so that cancer therapies are activated, enhanced and directed to the tumor. With Avenor, this platform can now be developed globally, across the United States, Europe and Asia.

A committed co-founding and leadership team.

Avenor's co-founders and leaders unite the people behind both platforms with oncology executives from the US and Europe, committed to delivering innovative solutions to patients:

- **Patrick Tricoli, PharmD, MBA**, Chief Executive Officer
- **Pierfrancesco Pavoni**, Chief Device Officer, founder of Medlogix
- **Pascal Schweizer, PhD**, acting Chief Financial Officer, co-founder of Thermosome
- **Frank Hermann, MD**, acting Chief Medical Officer, leading clinical development
- **Leonard A. Farber, MD**, Chief Medical Affairs and Market Access Officer
- **Kerstin Pino Tossi, PhD**, VP Operations and Business Development
- **Prof. Lars Lindner, MD**, Chair of the Scientific and Medical Advisory Board, co-founder of Thermosome, Sarcoma Center and Hyperthermia lead at LMU University Hospital Munich, Germany.

Patrick Tricoli, Pierfrancesco Pavoni and Pascal Schweizer form the founding Board of Directors of Avenor Therapeutics, Inc.

Early US traction at ASTRO 2026.

At the ASTRO 68th Annual Meeting in Boston (September 26–30, 2026), the Avenor team made its first appearance, introducing ALBA and its thermal-dose escalation approach to the US radiation oncology community. Radiation oncologists, medical physicists and leading US cancer centers engaged with Avenor on how planned, measured heat can add to radiotherapy and showed strong interest in the thermosensitive liposome (TSL) concept of using that heat to release drugs at the tumor. Both were early signs of the US market's readiness for bringing device and drug together.

"Our vision at Avenor is to harness physics to make heat a precise pillar of cancer care: planned and measured with the same rigor and predictability as radiation, and able to work alongside radiotherapy, chemotherapy, immunotherapy and our own heat-activated drugs," said Patrick Tricoli, Co-founder and CEO of Avenor. "By integrating seamlessly into existing treatment workflows, precision heat has the potential to enhance the effectiveness of cancer therapies while reducing toxicity. We are building the company that brings precision heat-activated oncology to patients."

What comes next.

Avenor is preparing its FDA Pre-Submission to open the regulatory dialogue on ALBA, initiating pricing and reimbursement work for US market access, deepening collaborations with major US institutions that have already expressed interest in its approach, and refining and growing its drug portfolio. Avenor will continue to partner with all stakeholders who support its vision and mission.

About Avenor Therapeutics

Avenor Therapeutics is a Cambridge, Massachusetts-based precision oncology company combining a clinically established hyperthermia device and a heat-activated tumor targeting drug platform. www.avenortx.com

ALBA is not cleared or approved by the US Food and Drug Administration and is not available for sale in the United States. THE001 is investigational and has not been approved by any regulatory authority. This release contains forward-looking statements subject to risks and uncertainties.

Media contact: press@avenortx.com

###